Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: A case report

Majd D. Jawad, Ronald S. Go, Rhett P. Ketterling, Kebede Begna, Kaaren K. Reichard, Min Shi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph-) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph- cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.

Original languageEnglish (US)
Pages (from-to)282-286
Number of pages5
JournalClinical Case Reports
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Protein-Tyrosine Kinases
Therapeutics
Neoplasms
Monosomy Chromosome 7
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Keywords

  • Chronic myelogenous leukemia
  • Monosomy 7

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy : A case report. / Jawad, Majd D.; Go, Ronald S.; Ketterling, Rhett P.; Begna, Kebede; Reichard, Kaaren K.; Shi, Min.

In: Clinical Case Reports, Vol. 4, No. 3, 01.03.2016, p. 282-286.

Research output: Contribution to journalArticle

Jawad, Majd D. ; Go, Ronald S. ; Ketterling, Rhett P. ; Begna, Kebede ; Reichard, Kaaren K. ; Shi, Min. / Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy : A case report. In: Clinical Case Reports. 2016 ; Vol. 4, No. 3. pp. 282-286.
@article{af6e999d5edf45aeba09970a6cbfb120,
title = "Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: A case report",
abstract = "Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph-) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph- cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.",
keywords = "Chronic myelogenous leukemia, Monosomy 7",
author = "Jawad, {Majd D.} and Go, {Ronald S.} and Ketterling, {Rhett P.} and Kebede Begna and Reichard, {Kaaren K.} and Min Shi",
year = "2016",
month = "3",
day = "1",
doi = "10.1002/ccr3.506",
language = "English (US)",
volume = "4",
pages = "282--286",
journal = "Clinical Case Reports",
issn = "2050-0904",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy

T2 - A case report

AU - Jawad, Majd D.

AU - Go, Ronald S.

AU - Ketterling, Rhett P.

AU - Begna, Kebede

AU - Reichard, Kaaren K.

AU - Shi, Min

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph-) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph- cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.

AB - Tyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph-) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph- cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.

KW - Chronic myelogenous leukemia

KW - Monosomy 7

UR - http://www.scopus.com/inward/record.url?scp=85033198604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033198604&partnerID=8YFLogxK

U2 - 10.1002/ccr3.506

DO - 10.1002/ccr3.506

M3 - Article

AN - SCOPUS:85033198604

VL - 4

SP - 282

EP - 286

JO - Clinical Case Reports

JF - Clinical Case Reports

SN - 2050-0904

IS - 3

ER -